Genfit SA Operating Income Over Time
| GNFT Stock | USD 5.97 0.00 0.00% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price. Is there potential for Biotechnology market expansion? Will Genfit introduce new products? Factors like these will boost the valuation of Genfit SA. Market participants price Genfit higher when confident in its future expansion prospects. Understanding fair value requires weighing current performance against future potential. All the valuation information about Genfit SA listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.90) | Revenue Per Share | Quarterly Revenue Growth (0.42) | Return On Assets | Return On Equity |
Investors evaluate Genfit SA using market value (trading price) and book value (balance sheet equity), each telling a different story. Calculating Genfit SA's intrinsic value - the estimated true worth - helps identify when the stock trades at a discount or premium to fair value. Analysts utilize numerous techniques to assess fundamental value, seeking to purchase shares when trading prices fall beneath estimated intrinsic worth. External factors like market trends, sector rotation, and investor psychology can cause Genfit SA's market price to deviate significantly from intrinsic value.
Please note, there is a significant difference between Genfit SA's value and its price as these two are different measures arrived at by different means. Investors typically determine if Genfit SA is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. Conversely, Genfit SA's market price signifies the transaction level at which participants voluntarily complete trades.
Cross Equities Operating Income Analysis
Compare Genfit SA and related stocks such as NeOnc Technologies, Protara Therapeutics, and Prelude Therapeutics Operating Income Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| NTHI | (3.3 M) | (3.3 M) | (3.3 M) | (3.3 M) | (3.3 M) | (3.3 M) | (3.3 M) | (3.3 M) | (3.3 M) | (3.3 M) | (3.3 M) | (3.3 M) | (2.8 M) | (12.2 M) | (7.1 M) | (6.4 M) | (6.7 M) |
| TARA | (8 M) | (8 M) | (8 M) | (7.1 M) | (7.6 M) | (20.9 M) | (28.7 M) | (30.4 M) | (26.1 M) | (15.3 M) | (34.4 M) | (47.5 M) | (67.1 M) | (43.6 M) | (49.2 M) | (44.2 M) | (46.5 M) |
| PRLD | (15 M) | (15 M) | (15 M) | (15 M) | (15 M) | (15 M) | (15 M) | (15 M) | (15 M) | (28.1 M) | (58.8 M) | (113.7 M) | (123.5 M) | (132.3 M) | (139.7 M) | (125.7 M) | (132 M) |
| IVVD | (112 M) | (112 M) | (112 M) | (112 M) | (112 M) | (112 M) | (112 M) | (112 M) | (112 M) | (112 M) | (112 M) | (226.9 M) | (248 M) | (212.8 M) | (176.9 M) | (159.2 M) | (167.1 M) |
| MDWD | (4.3 M) | (4.3 M) | (2.7 M) | (7.6 M) | (21.4 M) | (21.2 M) | (20.2 M) | (13.7 M) | (10.7 M) | 5.7 M | (8.8 M) | (11.2 M) | (7.7 M) | (15.5 M) | (19.4 M) | (17.4 M) | (18.3 M) |
| SLS | (2.4 M) | (20.8 M) | (21.2 M) | (33.8 M) | (36.6 M) | (34.2 M) | (16 M) | (15.7 M) | (31.6 M) | (20 M) | (17 M) | (25.3 M) | (42 M) | (37.9 M) | (31.5 M) | (28.4 M) | (29.8 M) |
| EPRX | (4.9 M) | (4.9 M) | (4.9 M) | (4.9 M) | (4.9 M) | (4.9 M) | (4.9 M) | (4.9 M) | (12 M) | (6.8 M) | (2.5 M) | (14.6 M) | (17.6 M) | (27.8 M) | (38.8 M) | (35 M) | (33.2 M) |
| IVA | (12.5 M) | (12.5 M) | (12.5 M) | (12.5 M) | (13.5 M) | (15.5 M) | (13 M) | (20.9 M) | (33.3 M) | (30.3 M) | (29.7 M) | (52.1 M) | (57.1 M) | (102.7 M) | (97.6 M) | (87.8 M) | (83.4 M) |
| ARMP | (5.4 M) | (3.9 M) | (4 M) | (15 M) | (14.1 M) | (10.2 M) | (23.4 M) | (16.2 M) | (12.5 M) | (19.1 M) | (21.6 M) | (23.8 M) | (36.9 M) | (40.9 M) | (42.4 M) | (38.2 M) | (36.3 M) |
| OBIO | (18.8 M) | (18.8 M) | (18.8 M) | (18.8 M) | (18.8 M) | (18.8 M) | (18.8 M) | (18.8 M) | (18.8 M) | (18.8 M) | (18.8 M) | (21.8 M) | (32.7 M) | (51.5 M) | (64.3 M) | (57.9 M) | (60.8 M) |
Genfit SA and related stocks such as NeOnc Technologies, Protara Therapeutics, and Prelude Therapeutics Operating Income description
Operating Income is the amount of profit realized from Genfit SA operations after accounting for operating expenses such as cost of goods sold (COGS), wages and depreciation. Operating income takes the gross income and subtracts other operating expenses and then removes depreciation. Operating Income of Genfit SA is typically a synonym for earnings before interest and taxes (EBIT) and is also commonly referred to as operating profit or recurring profit. Earnings before interest and taxes (EBIT), representing the amount of profit a company generates from its operations.My Equities
My Current Equities and Potential Positions
| Genfit SA | GNFT |
Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Business Address | Parc EurasantE, Loos, |
| Exchange | NASDAQ Exchange |
USD 5.97
Additional Tools for Genfit Stock Analysis
When running Genfit SA's price analysis, check to measure Genfit SA's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Genfit SA is operating at the current time. Most of Genfit SA's value examination focuses on studying past and present price action to predict the probability of Genfit SA's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Genfit SA's price. Additionally, you may evaluate how the addition of Genfit SA to your portfolios can decrease your overall portfolio volatility.